InvestorsObserver
×
News Home

Is Editas Medicine Inc (EDIT) a Stock to Watch After Losing 0.00% This Week?

Tuesday, March 19, 2024 12:30 PM | InvestorsObserver Analysts

Mentioned in this article

Is Editas Medicine Inc (EDIT) a Stock to Watch After Losing 0.00% This Week?

The market has been down on Editas Medicine Inc (EDIT) stock recently. EDIT gets a Bearish score from InvestorsObserver Stock Sentiment Indicator.

Sentiment Score - ,bearish
Editas Medicine Inc has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on EDIT!

What is Stock Sentiment?

Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score. As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend. Recent trends are a good indicator of current market sentiments. In its most basic form, stocks that are trending up are desirable by investors while stocks currently falling must be unattractive. InvestorsObserver's Sentimental Indicator tracks both changes in price and volume to analyze the most recent trends. Typically an increase in volume indicates ongoing trends are getting stronger, while a decrease in volume usually signals an end to the current trend. Available options can also represent current sentiments for a given stock. Since investors are able to bet on future trends of stocks using options, we consider the ratio of calls to puts when analyzing market sentiments .

What's Happening With EDIT Stock Today?

Editas Medicine Inc (EDIT) stock is trading at $7.85 as of 12:23 PM on Tuesday, Mar 19, an increase of $0.13, or 1.62% from the previous closing price of $7.72. The stock has traded between $7.60 and $7.98 so far today. Volume today is light. So far 658,134 shares have traded compared to average volume of 2,209,446 shares. To screen for more stocks like Editas Medicine Inc click here.

More About Editas Medicine Inc

Editas Medicine Inc is a gene-editing company. It is engaged in treating patients with genetically defined diseases by correcting disease-causing genes. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company's only operating segment is developing and commercializing genome editing technology. Click Here to get the full Stock Report for Editas Medicine Inc stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App